New Release: Alpha testing version has been released.

Prednisone

H02A - Corticosteroids for systemic use, plain ATC H02AB07 Small molecule approved 1955 Oral Prodrug Natural product

Active form: Prednisolone.

JFDA label: Prednisone 5 Tablets

Mechanism of Action

Agonist of Glucocorticoid receptor — Glucocorticoid receptor agonist

TargetActionGene / class
Glucocorticoid receptor efficacy AGONIST NR3C1

Indications

Approved

  • Allergic states
  • Delayed release only
  • Delayed-release only
  • Dermatologic diseases
  • Endocrine disorders
  • GI diseases
  • Hematologic disorders
  • Immediate-release only
  • Maintenance therapy
  • Miscellaneous
  • Neoplastic diseases
  • Nervous system (delayed-release only)
  • Ophthalmic diseases
  • Renal diseases
  • Respiratory diseases
  • Rheumatic disorders
  • Short-term therapy

Off-label

  • Acute exacerbation of chronic obstructive pulmonary disease (COPD)
  • Adjunctive therapy for pain management in immunocompetent patients with herpes zoster
  • Autoimmune hepatitis
  • Bell palsy
  • Duchenne muscular dystrophy
  • Giant cell arteritis
  • Glucocorticoid remediable aldosteronism, treatment
  • Graves orbitopathy
  • Pericarditis
  • Prostate cancer (metastatic)
  • Takayasu arteritis
  • Thyroiditis, subacute
  • Thyrotoxicosis (type 2 amiodarone-induced)

Contraindications

Source: Lexicomp

  • Hypersensitivity to prednisone or any component of the formulation Absolute
  • administration of live or live attenuated vaccines with immunosuppressive doses of prednisone Absolute
  • systemic fungal infections Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Cardiac disorders (2)

Not Known Cardiac failure (in susceptible patients) · hypertension

Nervous system disorders (7)

Not Known Emotional lability · headache · increased intracranial pressure (with papilledema) · myasthenia · psychiatric disturbance (including euphoria, insomnia, mood swings, personality changes, severe depression) · seizure · vertigo

Hepatobiliary disorders (3)

Not Known Increased serum alkaline phosphatase · increased serum ALT · increased serum AST

Blood and lymphatic system disorders (3)

Not Known Bruise · Kaposi’s sarcoma · petechia

Immune system disorders (2)

Not Known Anaphylaxis · hypersensitivity reaction

Metabolism and nutrition disorders (10)

Not Known Cushing’s syndrome · decreased serum potassium · diabetes mellitus · fluid retention · growth suppression (children) · hypokalemic alkalosis · hypothyroidism (enhanced) · menstrual disease · negative nitrogen balance (due to protein catabolism) · sodium retention

Gastrointestinal disorders (5)

Not Known Abdominal distention · carbohydrate intolerance · pancreatitis · peptic ulcer (with possible perforation and hemorrhage) · ulcerative esophagitis

Skin and subcutaneous tissue disorders (4)

Not Known Diaphoresis · facial erythema · skin atrophy · urticaria

Musculoskeletal and connective tissue disorders (7)

Not Known Amyotrophy · aseptic necrosis of bones (femoral and humeral heads) · osteoporosis · pathological fracture (long bones) · rupture of tendon (particularly Achilles tendon) · steroid myopathy · vertebral compression fracture

Eye disorders (4)

Not Known Exophthalmos · glaucoma · increased intraocular pressure · subcapsular posterior cataract

Infections and infestations (1)

Not Known Infection

General disorders and administration site conditions (1)

Not Known Wound healing impairment

Dosing

Source: Lexicomp

General dosing; anti-inflammatory/immunosuppressive/endocrine disorders: Oral: Initial: 5 to 60 mg daily: Note: Dose depends upon condition being treated and response of patient. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose. Prednisone taper (other regimens also available): Day 1: 30 mg divided as 10 mg before breakfast, 5 mg at lunch, 5 mg at dinner, 10 mg at bedtime Day 2: 5 mg at breakfast, 5 mg at lunch, 5 mg at dinner, 10 mg at bedtime Day 3: 5 mg 4 times daily (with meals and at bedtime) Day 4: 5 mg 3 times daily (breakfast, lunch, bedtime) Day 5: 5 mg 2 times daily (breakfast, bedtime) Day 6: 5 mg before breakfast Indication-specific dosing: Acute asthma (off-label dose): Oral: 40 to 60 mg/day for 3 to 10 days; administer as single or 2 divided doses (NAEPP 2007). Acute exacerbations of chronic obstructive pulmonary disease (COPD) (off-label use for immediate release products; off-label dose): Oral: 40 mg once daily for 5 days (GOLD 2014). Anaphylaxis, adjunctive treatment (off-label dose): Oral: 0.5 mg/kg (Lieberman 2005) Antineoplastic: Oral: Usual range: 10 mg daily to 100 mg/m2/day (depending on indication). Refer to specific protocol for dosing and administration details. Autoimmune hepatitis (off-label use): Oral: Initial: 60 mg daily for 1 week, followed by 40 mg daily for 1 week, then 30 mg daily for 2 weeks, then 20 mg daily. Half this dose should be given when used in combination with azathioprine (AASLD [Manns 2010]). Bell palsy (off-label use): Oral: 60 mg daily for 5 days, followed by a 5-day taper. Treatment should begin within 72 hours of onset of symptoms (OHNS [Baugh 2013]). Crohn disease, moderate/severe (off-label dose): Oral: 40 to 60 mg daily until resolution of symptoms and resumption of weight gain (usual duration: 7 to 28 days) (Lichtenstein 2009). Dermatomyositis/polymyositis (off-label dose): Oral: 1 mg/kg daily (range: 0.5 to 1.5 mg/kg/day), often in conjunction with steroid-sparing therapies; depending on response/tolerance, consider slow tapering after 2 to 8 weeks depending on response; taper regimens vary widely, but often involve 5 to 10 mg decrements per week and may require 6 to 12 months to reach a low once-daily or every-other-day dose to prevent disease flare (Briemberg 2003; Hengstman 2009; Iorizzo 2008; Wiendl 2008). Duchenne muscular dystrophy (off-label use): Oral: 0.75 mg/kg/day or 10 mg/kg/weekend, divided over 2 days. When used daily, the dose may be decreased to 0.3 mg/kg/day in patients who experience adverse reactions. Doses as high as 1.5 mg/kg/day have been studied, but there is no evidence that doses above 0.75 mg/kg/day provide greater efficacy (AAN [Gloss 2016]; Escolar 2011; Matthews 2016). Giant cell arteritis (off-label use): Oral: Initial: 40 to 60 mg daily; typically requires 1 to 2 years of treatment, but may begin to taper after 2 to 3 months; alternative dosing of 30 to 40 mg daily has d
(For additional information see "Prednisone: Pediatric drug information") General dosing; anti-inflammatory/immunosuppressive/endocrine disorders: Children and Adolescents: Oral: Refer to adult dosing. Note: Dose depends upon condition being treated and response of patient; dosage for infants and children should be based on severity of the disease and response of the patient rather than on strict adherence to dosage indicated by age, weight, or body surface area. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose. Indication-specific dosing: Acute asthma (off-label dose): Oral: Infants and Children Children ≥12 years and Adolescents: Refer to adult dosing. Antineoplastic: Children and Adolescents: Oral: Refer to adult dosing or to specific protocol. Autoimmune hepatitis (monotherapy or in combination with azathioprine) (off-label use): Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mg/kg/day for 2 weeks (maximum: 60 mg/day), followed by a taper over 6 to 8 weeks to a dose of 0.1 to 0.2 mg/kg/day or 2.5 to 5 mg daily (AASLD [Manns 2010]; Della Corte 2012). Bell palsy (off-label use): Infants, Children, and Adolescents Adolescents ≥16 years: Oral: Refer to adult dosing. Duchenne muscular dystrophy (off-label use): Children ≥ 4 years and Adolescents: Oral: 0.75 mg/kg/day or 10 mg/kg/weekend, divided over 2 days. The dose may be decreased to 0.3 mg/kg/day in patients who experience adverse reactions. Doses as high as 1.5 mg/kg/day have been studied, but there is no evidence that doses above 0.75 mg/kg/day provide greater efficacy (AAN [Gloss 2016]; Escolar 2011; Matthews 2016). Nephrotic syndrome; steroid sensitive (SSNS) (off-label dose): Children and Adolescents: Oral: Initial episode: 2 mg/kg/day or 60 mg/m2/day once daily, maximum daily dose: 60 mg/day for 4 to 6 weeks; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m2/dose on alternate days as a single dose, maximum dose: 40 mg/dose (Gipson 2009; KDIGO 2012; KDOQI 2013); duration of therapy based on patient response. Relapse: 2 mg/kg/day or 60 mg/m2/day once daily, maximum daily dose: 60 mg/day, continue until complete remission for at least 3 days; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m2/dose on alternate days as a single dose, maximum dose: 40 mg/dose, recommended duration of alternate day dosing is variable: may continue for at least 4 weeks then taper. Longer duration of treatment may be necessary in patients who relapse frequently, some patients may require up to 3 months of treatment (Gipson 2009; KDIGO 2012; KDOQI 2013). Maintenance therapy for frequently relapsing SSNS: Taper previous dose down to lowest effective dose which maintains remission using an alternate day schedule; usual effective range: 0.1 to 0.5 mg/kg/day on alternating days; other patients may require doses up to 0.7 mg/kg/dose every other day (KDIGO 2012; KDOQI 2013). Pne
Refer to adult dosing; use the lowest effective dose.
There are no dosage adjustments provided in the manufacturer’s labeling. Hemodialysis: Supplemental dose is not necessary.
There are no dosage adjustments provided in the manufacturer's labeling.

Warnings & Precautions

Source: Lexicomp

Adrenal suppression

May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving >20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections.

Anaphylactoid reactions

Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.

Immunosuppression

Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used to treat viral hepatitis or cerebral malaria. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Latent or active amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to corticosteroid initiation. Use with extreme caution in patients with Strongyloides infections; hyperinfection, dissemination and fatalities have occurred.

Kaposi sarcoma

Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).

Myopathy

Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.

Psychiatric disturbances

Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression or frank psychotic manifestations. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Disease-related concerns:

Cardiovascular disease

Use with caution in patients with HF and/or hypertension; long-term use has been associated with electrolyte disturbances, fluid retention, and hypertension. Use with caution in patients with a recent history of myocardial infarction (MI); left ventricular free wall rupture has been reported after the use of corticosteroids.

Diabetes

Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.

Gastrointestinal disease

Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis [nonspecific]) due to perforation risk.

Head injury

Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.

Hepatic impairment

Use with caution in patients with hepatic impairment, including cirrhosis; effects may be enhanced.

Myasthenia gravis

Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.

Ocular disease

Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.

Osteoporosis

Use with caution in patients with or who are at risk for osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.

Renal impairment

Use with caution in patients with renal impairment; fluid retention may occur.

Seizure disorders

Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.

Thyroid disease

Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Concurrent drug therapy issues:

Drug-drug interactions

Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Special populations:

Elderly

Use with caution in the elderly with the smallest possible effective dose for the shortest duration.

Pediatric

May affect growth velocity; growth and development should be routinely monitored in pediatric patients. Dosage form specific issues:

Benzyl alcohol and derivatives

Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

Propylene glycol

Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007). Other warnings/precautions:

Discontinuation of therapy

Withdraw therapy with gradual tapering of dose.

Stress

Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).

Pregnancy & Lactation

Pregnancy

FDA category C Teratogenic

Caution

As for prednisolone. Use lowest effective dose

Lactation

Compatible

Prednisone and its metabolite, prednisolone, are present in breast milk. Actual concentrations are dependent upon maternal dose (Berlin 1979; Katz 1975; Sagraves 1981). Peak concentrations of prednisone and prednisolone in breast milk occur ~2 hours after an oral maternal dose (Berlin 1979; Sagraves 1981); the half-life in breast milk is 1.9 hours (prednisone) and 4.2 hours (prednisolone) (Sagraves 1981). In a study which included six mother-infant pairs, adverse events were not observed in nu

Monitoring

Clinical pearlBlood pressure; weight; serum glucose; electrolytes; growth in pediatric patients; presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); Hgb, occult blood loss; chest x-ray (at regular intervals during prolonged therapy); IOP with therapy >6 weeks.

Chemistry & Properties

2D structure
FormulaC21H26O5
Molecular weight358.43 g/mol
IUPAC name(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
CAS53-03-2
PubChem CID5865
InChIKeyXOFYZVNMUHMLCC-ZPOLXVRWSA-N
logP1.77 (XLogP 1.5)
Polar surface area91.67 Ų
H-bond acceptors / donors5 / 2
Drug-likeness (QED)0.78
Lipinski violations0
SMILESC[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability70.0%
Half-life2.158 h
Volume of distribution0.763 L/kg
Protein binding80.8%
BBB penetrantNo

Enzyme interactions

EnzymeRoleDetail
CYP2C19Substrate
CYP2C8Inhibitor
CYP3A4Substrate

Receptor binding (top 1)

TargetActionAffinity
Glucocorticoid receptor (NR3C1) Agonist pKi 6.3

Transporters

ASBT (Inhibitor)BCRP (Inhibitor)BCRP (Inhibitor)BSEP (Inhibitor)MDR1 (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)OATP1A2 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)OCT1 (Inhibitor)OCT3 (Inhibitor)P-gp (Inhibitor)MDR1 (Substrate)P-gp (Substrate)

Drug–drug interactions (100+, DDInter)

Interacting drugSeverityManagement
Adalimumab major
Bacillus calmette-guerin substrain tice live antigen major
Baricitinib major
Bempedoic acid major
Brexucabtagene autoleucel major
Bupropion major
Certolizumab pegol major
Cinoxacin major
Ciprofloxacin major
Cladribine major
Deferasirox major
Delafloxacin major
Desirudin major
Desmopressin major
Dinutuximab major
Enoxacin major
Etanercept major
Fingolimod major
Gatifloxacin major
Gemifloxacin major
Golimumab major
Grepafloxacin major
Infliximab major
Leflunomide major
Levofloxacin major
Lomefloxacin major
Lumateperone major
Measles virus vaccine live attenuated major
Mifepristone major
Moxifloxacin major
Mumps virus strain B level jeryl lynn live antigen major
Nalidixic acid major
Natalizumab major
Norfloxacin major
Ofloxacin major
Ozanimod major
Rotavirus vaccine major
Rubella virus vaccine major
Siponimod major
Smallpox (Vaccinia) Vaccine, Live major

Showing 40 of 100+.

Registered Products (1)

BrandForm / strengthPackAgentCitizen (JOD)
Prednisone 5 Tablets Tablet 5 mg 100 tab Hikma Pharmaceuticals Co.Ltd/Jordan 1.500